RadNet, Inc.

RadNet, Inc. (RDNT) Market Cap

RadNet, Inc. has a market capitalization of $4.69B.

Financials based on reported quarter end 2025-12-31

Price: $60.39

0.30 (0.50%)

Market Cap: 4.69B

NASDAQ · time unavailable

CEO: Howard G. Berger

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 1997-01-03

Website: https://www.radnet.com

RadNet, Inc. (RDNT) - Company Information

Market Cap: 4.69B · Sector: Healthcare

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Analyst Sentiment

88%
Strong Buy

Based on 8 ratings

Analyst 1Y Forecast: $87.86

Average target (based on 3 sources)

Consensus Price Target

Low

$90

Median

$92

High

$95

Average

$92

Potential Upside: 52.3%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 RADNET INC (RDNT) — Investment Overview

🧩 Business Model Overview

RadNet Inc (RDNT) is the largest provider of outpatient diagnostic imaging services in the United States. The company operates and manages a national network of imaging centers offering a comprehensive suite of radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, ultrasound, digital mammography, and X-ray. RadNet’s model is predominantly centered on the ownership and operation of these centers, with a focus on both organic growth in existing markets and strategic expansion via acquisitions. By consolidating a fragmented space, RadNet aims to achieve scale advantages, operational efficiencies, and local area dominance.

💰 Revenue Streams & Monetisation Model

RadNet generates revenue primarily from fees charged for diagnostic imaging procedures performed at its centers. These fees are typically reimbursed by a mix of commercial payors, government programs (including Medicare and Medicaid), and patient direct payments. The company enters into payer contracts to secure negotiated rates, and, in some cases, establishes capitation contracts with health maintenance organizations (HMOs) under which RadNet receives fixed payments per member in exchange for all necessary imaging services. Additionally, RadNet operates under joint venture models with hospitals, leveraging its expertise and scale to manage imaging operations for partner health systems and increasing its addressable market outside of wholly-owned centers. The monetisation model is designed to drive volume utilization while managing per-procedure cost. Technology investments in workflow and scheduling, as well as centralized billing and revenue cycle management, help optimize center occupancy, reduce administrative friction, and improve receivable collection.

🧠 Competitive Advantages & Market Positioning

RadNet holds a leading position in the consolidating U.S. diagnostic imaging market. Its scale provides several competitive advantages: - **Network Density:** RadNet’s deep penetration in key metropolitan areas strengthens referral relationships with physicians and health systems, enhancing patient throughput. - **Cost Efficiency:** A broad operational footprint supports investment in centralized administration, IT, and procurement, yielding margin advantages over smaller competitors. - **Technology & Clinical Innovation:** Investment in advanced imaging modalities and artificial intelligence (AI) for image processing positions RadNet to offer higher-value services and operational efficiencies. - **Exclusive Partnerships:** Joint ventures and alliances with hospitals and large physician groups create defensible, recurring patient flow channels. - **Regulatory and Compliance Infrastructure:** Expertise in navigating radiology-specific regulatory, licensure, and reimbursement dynamics serves as a barrier to entry for new market entrants. Overall, RadNet occupies a unique intersection as both a technology-enabled healthcare provider and a consolidator, supporting durable market share gains.

🚀 Multi-Year Growth Drivers

Several secular and company-specific trends underpin RadNet’s multi-year growth trajectory: - **Aging Population:** The rising proportion of elderly Americans leads to increased utilization of diagnostic imaging, particularly in oncology, cardiology, and orthopedics. - **Shift from Hospital to Outpatient Settings:** Hospitals continue to outsource imaging or redirect imaging to lower-cost outpatient providers, benefiting RadNet’s ambulatory center footprint. - **Expansion of Value-Based Care:** Capitation and risk-sharing models align incentives around cost-efficient imaging, making RadNet an attractive partner for payors and provider networks. - **Geographic Expansion and Industry Consolidation:** The fragmented nature of the U.S. outpatient imaging market supports RadNet’s ongoing strategy of acquiring independent centers and expanding into new high-growth geographies. - **Technology Integration and AI Adoption:** Investments in AI-driven workflow (including image interpretation and scheduling optimization) increase throughput, reduce errors, and support teleradiology/stretch capacity during physician shortages. - **Precision Medicine and Advanced Modalities:** As medicine becomes more personalized, demand rises for advanced imaging services—including PET, molecular imaging, and image-guided interventions—expanding the company’s addressable market. These drivers provide a long runway for volume growth, margin improvement, and increased share of U.S. radiology spend.

⚠ Risk Factors to Monitor

Investors should be mindful of the following risks that could affect RadNet’s outlook: - **Reimbursement Pressure:** Changes in Medicare, Medicaid, or commercial payor reimbursement rates for imaging services can significantly impact revenues and margins. - **Regulatory Exposure:** Imaging is highly regulated, with evolving requirements around physician licensing, patient privacy (HIPAA), and safety standards. - **Technology Disruption:** Advances in imaging hardware, teleradiology, or new AI entrants could introduce competition, requiring ongoing innovation and investment. - **Provider Contracts & Referral Patterns:** Loss of key contracts with referring physicians, hospital systems, or payors could lead to material drops in volume. - **Integration Execution:** RadNet’s acquisition-heavy growth strategy carries risks around integration, culture, and realization of synergies. - **Radiologist Labor Market:** Shortages or increasing compensation for radiologists could pressure costs or affect service delivery. Mitigating these risks requires disciplined management, proactive compliance, and ongoing investment in technology and partnerships.

📊 Valuation & Market View

RadNet’s valuation framework is typically benchmarked against a blend of earnings-based (EBITDA, adjusted net income) and revenue-based metrics, reflecting both its operational leverage and recurring healthcare services revenue streams. As the largest participant in its market, RadNet often commands a premium to smaller peers due to its scale, historical growth, and demonstrated M&A execution. Market participants tend to focus on: - **Organic Center Volume Growth** - **Margin Expansion from Operational Efficiencies** - **Pace and Success of Accretive Acquisitions** - **Adoption and Monetization of AI Tools** - **Free Cash Flow Conversion and Leverage Ratios** The market generally views companies with RadNet’s attributes—defensive healthcare demand, scalability, and technology-forward strategy—as attractive within the broader healthcare services and outpatient provider universes. Valuation multiples have reflected optimism regarding sustained volume growth and the ability to consolidate a still-fragmented market.

🔍 Investment Takeaway

RadNet stands out as a dominant force in the U.S. outpatient diagnostic imaging space, driven by its scale, sophisticated care delivery model, and commitment to technology. The company is well-positioned to capitalize on secular healthcare trends favoring outpatient services, industry consolidation, and the increasing complexity and frequency of imaging as part of population health management. Growth opportunities remain tied to leverageable operating platforms, efficient integration of acquisitions, and leveraging advances in AI and imaging modalities to optimize margins and clinical value. The defensive, recurring nature of its revenue, combined with multiple secular tailwinds, support a positive multi-year investment thesis. Potential investors should monitor execution on integration, payer dynamics, and regulatory headwinds, but RadNet represents a compelling opportunity to participate in the evolution of value-based, technology-enabled healthcare delivery.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"For the fiscal year ending December 31, 2025, RDNT reported revenue of $547.7M, with a net loss of $597k and an earnings per share (EPS) of $-0.0078. The company generated an operating cash flow of $84.2M but posted significant capital expenditures of $315.0M, resulting in negative free cash flow of $230.9M. RDNT's balance sheet shows total assets of $3.76B against total liabilities of $2.40B, leaving total equity at $1.36B and a net debt of $1.09B. Despite a revenue generation capacity indicated by the substantial revenue figure, RDNT has struggled to achieve profitability, with a negative net income reflecting ongoing operational challenges. Shareholder returns appear limited as no dividends have been paid, and a 1-year stock price change of 15.51% indicates modest price appreciation. Overall, while the company is generating a significant amount of revenue, it faces hurdles in profitability and cash flow, which will be critical for future growth."

Revenue Growth

Neutral

Solid revenue generation of $547.7M.

Profitability

Neutral

Negative net income indicates profitability challenges.

Cash Flow Quality

Neutral

Negative free cash flow signals operational inefficiencies.

Leverage & Balance Sheet

Neutral

Healthy equity position but high debt levels.

Shareholder Returns

Neutral

No dividends paid; moderate price performance.

Analyst Sentiment & Valuation

Fair

Mixed outlook with slight positive sentiment on revenue.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

RadNet delivered record Q4 revenue and adjusted EBITDA, driven by strong advanced imaging volumes and favorable modality mix, while Digital Health continued to scale. Liquidity and leverage remain conservative, supporting ongoing M&A and de novo expansion. 2026 guidance calls for double-digit Imaging Center growth with margin improvement, robust Digital Health expansion, rising ARR, and multiple expected FDA clearances. The acquisition of Gleamer strengthens DeepHealth’s global AI leadership. Management acknowledged labor and weather headwinds but maintained a confident outlook.

Growth

  • Q4 revenue up 14.8% to $547.7M; adjusted EBITDA up 16.9% to $87.7M (company records)
  • Digital Health Q4 revenue up 48.2% to $27.9M; adjusted EBITDA up 8.9% to $4.9M
  • Advanced imaging volumes up 14.1% aggregate and 9.6% same-center YoY in Q4
  • Advanced imaging mix rose 178 bps to 28.6% of procedures
  • Digital Health ARR at 12/31/25: $75.4M; targeted to approach ~$140M by YE 2026 (incl. ~+$30M from Gleamer)

Business Development

  • Acquired Paris-based Gleamer to integrate into DeepHealth; expands clinical AI breadth and global footprint
  • Acquired iCAD in 2025; integrated C-MODE and CMAR into DeepHealth portfolio
  • Post-year-end 2026: acquired 13 centers in Southwest Florida, 6 in Indiana (Northwest Radiology), and 1 in Virginia
  • Opened 7 de novo imaging centers in 2025 to address capacity and access needs
  • Expanded multiple health system JVs in 2025; in discussions to establish additional JV partnerships

Financials

  • Q4 adjusted EPS $0.23 vs. $0.24 prior year (essentially flat)
  • Met or exceeded 2025 guidance (Imaging Center revenue, adjusted EBITDA, free cash flow); Digital Health FY revenue $92.7M and adjusted EBITDA $15.5M within guidance
  • Days sales outstanding improved to a record low 29.5 days
  • Shift toward higher-acuity modalities drove revenue per procedure and margin gains

Capital & Funding

  • Year-end 2025 cash balance $767M; full availability on $282M revolver
  • Term loan priced at SOFR + 225 bps
  • Net debt $323.5M (includes RDNT’s 49% share of NJIN net debt of $27.8M); net leverage ~1.0x adjusted EBITDA
  • Management remains committed to low leverage while pursuing M&A

Operations & Strategy

  • Leveraging TechLive and AI-powered dynamic scheduling to improve throughput and modality mix
  • Strategy to apply AI across every procedure for efficiency, accuracy, and workflow optimization
  • DeepHealth platform positioning as end-to-end radiology workflow (acquisition to reporting) with clinical and agentic AI
  • Investing in sales, marketing, and implementation teams to scale Digital Health
  • Health system partnerships: 151 of 418 centers (36.1%) within JV structures aiding physician referral channels

Market & Outlook

  • Continued shift of imaging volumes from hospitals to cost-effective freestanding centers
  • Growing imaging demand globally amid persistent labor shortages in radiology
  • 2026 guidance: Imaging Center revenue growth 17%–19% YoY; EBITDA growth to outpace revenue, driving margin expansion
  • 2026 free cash flow expected to grow 29%–41% YoY
  • Digital Health 2026 revenue growth expected at 45%–55%; share of segment revenue from internal RDNT centers to decline from 45% (2025) to ~33% (2026)
  • At least four anticipated FDA clearances in 2026 (mammography, lung, prostate, thyroid, brain, musculoskeletal)

Risks Or Headwinds

  • Constrained labor market for technologists, administrative staff, and radiologists
  • Integration of multiple acquisitions (iCAD, C-MODE, CMAR, Gleamer) including previously negative-EBITDA assets
  • Same-center labor cost inflation embedded at ~4% for 2026
  • Severe winter weather impacts in Mid-Atlantic and Northeast factored into 2026 outlook

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the RDNT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (RDNT)

© 2026 Stock Market Info — RadNet, Inc. (RDNT) Financial Profile